Back to search
FDAFDA · Food and drugs·Recall number D-607-2013

Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.

Published June 26, 2013 · Recall initiated: May 31, 2013

Summary

FDA records drug Class III recall D-607-2013, published June 26, 2013 and initiated May 31, 2013. Recalling firm: Pfizer Inc; Status: Terminated; Reported quantity: 5,410 botlles; Lot: Lot #: a) C120138, Exp 07/13; b) C120137, Exp 07/13. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specification

What to do

Voluntary: Firm initiated · Letter

Get an email if NORPACE CR has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NORPACE CR
Manufacturer
Pfizer Inc
Distributor
Nationwide and Puerto Rico
UPC
0300252752314
Lot
Lot #: a) C120138, Exp 07/13; b) C120137, Exp 07/13
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017. recalled?

Yes. FDA published recall D-607-2013 on June 26, 2013. Reported hazard: Failed Dissolution Specification

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NORPACE CR. UPC: 0300252752314.